ArticleThe Indian journal of medical research2025
An analysis of novel endothelial biomarkers to ascertain their role as prognostic indicators in severe COVID-19 illness.
Article in The Indian journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & objectives COVID-19 is a complex disease that affects multiple systems and causes inflammation due to the SARS-CoV-2 virus's attraction to ACE-2 receptors. The severity of the disease ranges from mild upper respiratory tract infections to multi-organ failure and disseminated intravascular coagulation. Critical clinical features, such as respiratory failure, myocarditis, acute kidney injury, and a hypercoagulable state, are common in severe COVID-19 illness. Identifying patients at higher risk of rapid disease progression leading to severe complications and death is crucial. Available biomarkers lack specificity and accuracy in identifying the severity of COVID-19 infections. Therefore, there is a need to identify specific endothelial biomarkers that can predict early organ damage, facilitate effective management of patients, and categorise multisystem involvement during COVID-19 infection. Methods The participants constituted laboratory-confirmed COVID-19-positive patients with influenza-like illness (ILI) features under home isolation or moderate to severe acute respiratory infection (SARI) manifestations requiring admission. The chosen markers were analysed using the Human Luminex multiplex bead-based assay system. Results Our study revealed that certain markers, such as intercellular adhesion molecule (ICAM) and Galectin-3 were elevated in all COVID-19-positive patients, while others, like vascular cell adhesion molecule (VCAM), Angiopoietin-2, Thrombomodulin, and tumour necrosis factor receptor 1 (TNFR1) were specifically elevated in patients requiring admission. Such findings indicated the potential of some biomarkers in disease prognostication. Interpretation & conclusions Effective management of COVID-19 requires proper risk stratification. The findings of our investigation underscore the necessity for additional research to confirm the clinical utility and importance of these biomarkers and to fully leverage their capabilities in informing the management of severe COVID-19 disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.